## 1

#### Pharma innovation high now – monetary incentive is the biggest factor.

**Swagel 21** Phillip L. Swagel, Director of the Congressional budget office 4-xx-2021, "Research and Development in the Pharmaceutical Industry," Congressional Budget Office, <https://www.cbo.goc/publication/57126#_idTextAnchor020> SJ//DA

**Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.** In this report, the Congressional Budget Office assesses trends in spending for drug research and development (R&D) and the introduction of new drugs. CBO also examines factors that determine how much drug companies spend on R&D: expected global revenues from a new drug; cost to develop a new drug; and federal policies that affect the demand for drug therapies, the supply of new drugs, or both. What Are Recent Trends in Pharmaceutical R&D and New Drug Approvals? T**he pharmaceutical industry devoted $83 billion to R&D expenditures in 2019. Those expenditures covered a variety of activities, including discovering and testing new drugs, developing incremental innovations such as product extensions, and clinical testing for safety-monitoring or marketing purposes. That amount is about 10 times what the industry spent per year in the 1980s, after adjusting for the effects of inflation.** The share of revenues that drug companies devote to R&D has also grown: **On average, pharmaceutical companies spent about one-quarter of their revenues (net of expenses and buyer rebates) on R&D expenses** in 2019, which is **almost twice as large a share of revenues as they spent in 2000.** That revenue share is larger than that for other knowledge-based industries, such as semiconductors, technology hardware, and software. The number of new drugs approved each year has also grown over the past decade. On averace, the Food and Drug Administration (FDA) approved 38 new drugs per year from 2010 through 2019 (with a peak of 59 in 2018), which is 60 percent more than the yearly average over the previous decade. **Many of the drugs that have been approved in recent years are “specialty drugs.” Specialty drugs generally treat chronic, complex, or rare conditions, and they may also require special handling or monitoring of patients**. Many specialty drugs are biologics (large-molecule drugs based on living cell lines), **which are costly to develop, hard to imitate, and frequently have high prices.** Previously, most drugs were small-molecule drugs based on chemical compounds. Even while they were under patent, those drugs had lower prices than recent specialty drugs have. Information about the kinds of drugs in current clinical trials indicates that much of the industry’s innovative activity is focused on specialty drugs that would provide new cancer therapies and treatments for nervous-system disorders, such as Alzheimer’s disease and Parkinson’s disease. **What Factors Influence Spending for R&D?** Drug companies’ R&D spending decisions depend on three main factors: Anticipated lifetime global revenues from a new drug, **Expected costs to develop a new drug**, and Policies and programs that influence the supply of and demand for prescription drugs. Various considerations inform companies’ expectations about a drug’s revenue stream, including the anticipated prices it could command in different markets around the world and the expected global sales volume at those prices (given the number of people who might use the drug). The prices and sales volumes of existing drugs provide information about consumers’ and insurance plans’ willingness to pay for drug treatments. Importantly, when drug companies set the prices of a new drug, they do so to maximize future revenues net of manufacturing and distribution costs. A drug’s sunk R&D costs—that is, the costs already incurred in developing that drug—do not influence its price. **Developing new drugs is a costly and uncertain process, and many potential drugs never make it to market. Only about 12 percent of drugs entering clinical trials are ultimately approved for introduction by the FDA. In recent studies, estimates of the average R&D cost per new drug range from less than $1 billion to more than $2 billion per drug**. Those estimates include the costs of both laboratory research and clinical trials of successful new drugs as well as expenditures on drugs that do not make it past the laboratory-development stage, that enter clinical trials but fail in those trials or are withdrawn by the drugmaker for business reasons, or that are not approved by the FDA. Those estimates also include the company’s capital costs—the value of other forgone investments—incurred during the R&D process. Such costs can make up a substantial share of the average total cost of developing a new drug. The development process often takes a decade or more, and during that time the company does not receive a financial return on its investment in developing that drug. The federal government affects R&D decisions in three ways. First, it increases demand for prescription drugs, which encourages new drug development, by fully or partially subsidizing the purchase of prescription drugs through a variety of federal programs (including Medicare and Medicaid) and by providing tax preferences for employment-based health insurance. Second, the federal government increases the supply of new drugs. It funds basic biomedical research that provides a scientific foundation for the development of new drugs by private industry. Additionally, tax credits—both those available to all types of companies and those available to drug companies for developing treatmentscof uncommon diseases—provide incentives to invest in R&D. Similarly, deductions for R&D investment can be used to reduce tax liabilities immediately rather than over the life of that investment. Finally, the patent system and certain statutory provisions that delay FDA approval of generic drugs provide pharmaceutical companies with a period of market exclusivity, when competition is legally restricted. During that time, they can maintain higher prices on a patented product than they otherwise could, which makes new drugs more profitable and thereby increases drug companies’ incentives to invest in R&D. Third, some federal policies affect the number of new drugs by influencing both demand and supply. For example, federal recommendations for specific vaccines increase the demand for those vaccines and provide an incentive for drug companies to develop new ones. Additionally, federal regulatory policies that influence returns on drug R&D can bring about increases or decreases in both the supply of and demand for new drugs. Trends in R&D Spending and New Drug Development Private spending on pharmaceutical R&D and the approval of new drugs have both increased markedly in recent years, resuming a decades-long trend that was interrupted in 2008 as generic versions of some top-selling drugs became available and as the 2007–2009 recession occurred. **In particular, spending on drug R&D increased by nearly 50 percent between 2015 and 2019.** Many of the drugs approved in recent years are high-priced specialty drugs for relatively small numbers of potential patients. By contrast, the top-selling drugs of the 1990s were lower-cost drugs with large patient populations. R&D Spending R&D spending in the pharmaceutical industry covers a variety of activities, including the following: Invention, or research and discovery of new drugs; Development, or clinical testing, preparation and submission of applications for FDA approval, and design of production processes for new drugs; Incremental innovation, including the development of new dosages and delivery mechanisms for existing drugs and the testing of those drugs for additional indications; Product differentiation, or the clinical testing of a new drug against an existing rival drug to show that the new drug is superior; and Safety monitoring, or clinical trials (conducted after a drug has reached the market) that the FDA may require to detect side effects that may not have been observed in shorter trials when the drug was in development. In real terms**, private investment in drug R&D among member firms of the Pharmaceutical Research and Manufacturers of America (PhRMA), an industry trade association, was about $83 billion in 2019, up from about $5 billion in 1980 and $38 billion in 2000**.1 Although those spending totals do not include spending by many smaller drug companies that do not belong to PhRMA, the trend is broadly representative of R&D spending by the industry as a whole.2 A survey of all U.S. pharmaceutical R&D spending (including that of smaller firms) by the National Science Foundation (NSF) reveals similar trends.3 Although total R&D spending by all drug companies has trended upward, small and large firms generally focus on different R&D activities. **Small companies not in PhRMA devote a greater share of their research to developing and testing new drugs,** many of which are ultimately sold to larger firms (see Box 1). By contrast, a greater portion of the R&D spending of larger drug companies (including those in PhRMA) is devoted to conducting clinical trials, developing incremental “line extension” improvements (such as new dosages or delivery systems, or new combinations of two or more existing drugs), and conducting postapproval testing for safety-monitoring or marketing purposes.

#### The aff crushes innovation in the pharma sector---incentivizes them to focus on non-important issues.

Glassman 21 [Amanda; 5/6/21; Executive vice president and a senior fellow at the Center for Global Development, a nonpartisan, nonprofit think tank in Washington and London; “*Big Pharma Is Not the Tobacco Industry*,” Barron, <https://www.barrons.com/articles/big-pharma-is-not-the-tobacco-industry-51620315693>] Justin

But here is the crux of the problem: The pharmaceutical industry is not the tobacco industry. They are not merchants of death. The companies are amoral and exist to make money, but their business is not fundamentally immoral. Big Pharma (mostly) develops and sells products that people need to survive and thrive. Their products improve health and welfare. Fights over access to medicines are possible because medicines exist in the first place—medicines that were usually developed by Big Pharma. And yes, the pharmaceutical industry benefits from public subsidy and publicly financed foundational research. But the companies also put their own capital at risk to develop new products, some of which offer enormous public benefits. In fact, several of them did just that in the pandemic: invested their own money to develop patented manufacturing technologies in record time. Those technologies are literally saving the world right now. Public funding supported research and development, but companies also brought their own proprietary ingenuity and private investments to bear toward solving the world’s singular, collective challenge. Their reward should be astronomical given the insane scale of the health and economic benefits these highly efficacious vaccines produce every day. Market incentives sent a clear signal that further needed innovation—greater efficacy, single doses, more-rapid manufacturing, updated formulations, fast boosters, and others—would be richly rewarded. Market incentives could also have been used to lubricate supply lines and buy vaccines on behalf of the entire world; with enough money, incredible things can happen. But activist lobbying to waive patents—a move the Biden administration endorsed yesterday—sends exactly the opposite signal. It says that the most important, valuable innovations will be penalized, not rewarded. It tells innovators, don’t bother attacking the most important global problems; instead, throw your investment dollars at the next treatment for erectile disfunction, which will surely earn you a steady return with far less agita. It is worth going back to first principles. What problem are we trying to solve? We have highly efficacious vaccines that we would like to get out to the entire world as quickly as possible to minimize, preventable disease and deaths address atrocious inequities, and enable the reopening of society, trade, and commerce. Hundreds of millions of people have been plunged into poverty over the past year; in the developing world, the pandemic is just getting started. What is the quickest way to get this done? Vaccine manufacturing is not just a recipe; if you attack and undermine the companies that have the know-how, do you really expect they’ll be eager to help you set up manufacturing elsewhere? Is the plan to march into Pfizer and force its staff to redeploy to Costa Rica to build a new factory? Do the U.S. administration or activists care that this decision could take years to negotiate at the World Trade Organization, and will likely be litigated for years thereafter? Does it make sense to eliminate the incentive for private companies to invest in vaccine R&D or in the response to the next health emergency? And if the patent waiver is only temporary and building a factory takes months or years, will anyone bother to do so, even if they could? No, none of it makes sense. Worse still, we could solve the policy problem more easily by harnessing market incentives for the global good by ponying up cash to vaccinate the entire world. No confiscation necessary.

#### Pharma Innovation prevents Extinction – checks new diseases.

Engelhardt 8, H. Tristram. Innovation and the pharmaceutical industry: critical reflections on the virtues of profit. M & M Scrivener Press, 2008 (doctorate in philosophy (University of Texas at Austin), M.D. (Tulane University), professor of philosophy (Rice University), and professor emeritus at Baylor College of Medicine)

Many are suspicious of, or indeed jealous of, the good fortune of others. Even when profit is gained in the market without fraud and with the consent of all buying and selling goods and services, there is a sense on the part of some that something is wrong if considerable profit is secured. There is even a sense that good fortune in the market, especially if it is very good fortune, is unfair. One might think of such rhetorically disparaging terms as "wind-fall profits". There is also a suspicion of the pursuit of profit because it is often embraced not just because of the material benefits it sought, but because of the hierarchical satisfaction of being more affluent than others. The pursuit of profit in the pharmaceutical and medical-device industries is tor many in particular morally dubious because it is acquired from those who have the bad fortune to be diseased or disabled. Although the suspicion of profit is not well-founded, this suspicion is a major moral and public-policy challenge. Profit in the market for the pharmaceutical and medical-device industries is to be celebrated. This is the case, in that if one is of the view (1) that the presence of additional resources for research and development spurs innovation in the development of pharmaceuticals and med-ical devices (i.e., if one is of the view that the allure of **profit is one of the most effective ways not only to acquire resources but productively to direct human energies** in their use), (2) that given the limits of altruism and of the willingness of persons to be taxed, the possibility of profits is necessary to secure such resources, (3) that the allure of profits also tends to enhance the creative use of available resources in the pursuit of phar-maceutical and medical-device innovation, and (4) if one judges it to be the case that such innovation is both necessary to maintain the human species in an ever-changing and always dangerous environment in which new microbial and other threats may at any time emerge to threaten human well-being, if not survival (i.e., that such innovation is necessary to prevent increases in morbidity and mortality risks), as well as (5) in order generally to decrease morbidity and mortality risks in the future, it then follows (6) that one should be concerned regarding any policies that decrease the amount of resources and energies available to encourage such innovation. One should indeed be of the view that the possibilities for profit, all things being equal, should be highest in the pharmaceutical and medical-device industries. Yet, there is a suspicion regarding the pursuit of profit in medicine and especially in the pharmaceutical and medical-device industries.

#### Pharma spills-over – has cascading global impacts that are necessary for human survival.

NAS 8 National Academy of Sciences 12-3-2008 “The Role of the Life Sciences in Transforming America's Future Summary of a Workshop” //Re-cut by Elmer

Fostering Industries to Counter Global Problems The life sciences have applications in areas that range far beyond human health. Life-science based approaches could **contribute to advances in** many industries, from energy production and pollution remediation, to clean manufacturing and the production of new biologically inspired materials. In fact, biological systems could provide the basis for new products, services and industries that we cannot yet imagine. Microbes are already producing biofuels and could, through further research, provide a major component of future energy supplies. Marine and terrestrial organisms extract carbon dioxide from the atmosphere, which suggests that biological systems could be used to help manage climate change. Study of the complex systems encountered in biology is decade, it is really just the beginning.” Advances in the underlying science of plant and animal breeding have been just as dramatic as the advances in genetic can put down a band of fertilizer, come back six months later, and plant seeds exactly on that row, reducing the need for fertilizer, pesticides, and other agricultural inputs. Fraley said that the global agricultural system needs to adopt the goal of doubling the current yield of **crops while reducing key inputs like pesticides, fertilizers, and water** by one third. “It is more important than putting a man on the moon,” he said. Doubling agricultural yields would “change the world.” Another billion people will join the middle class over the next decade just in India and China as economies continue to grow. And all people need and deserve secure access to food supplies. Continued progress will require both basic and applied research, The evolution of life “put earth under new management,” Collins said. Understanding the future state of the planet will require understanding the biological systems that have shaped the planet. Many of these biological systems are found in the oceans, which cover 70 percent of the earth’s surface and have a crucial impact on weather, climate, and the composition of the atmosphere. In the past decade, new tools have become available to explore the microbial processes that drive the **chemistry of the oceans**, observed David Kingsbury, Chief Program Officer for Science at the Gordon and Betty Moore Foundation. These technologies have revealed that a large proportion of the planet’s genetic diversity resides in the oceans. In addition, many organisms in the oceans readily exchange genes, creating evolutionary forces that can have global effects. The oceans are currently under great stress, Kingsbury pointed out. Nutrient runoff from agriculture is helping to create huge and expanding “dead zones” where oxygen levels are too low to sustain life. Toxic algal blooms are occurring with higher frequency in areas where they have not been seen in the past. Exploitation of ocean resources is disrupting ecological balances that have formed over many millions of years. Human-induced changes in the chemistry of the atmosphere are changing the chemistry of the oceans, with potentially catastrophic consequences. “If we are not careful, we are not going to have a sustainable planet to live on,” said Kingsbury. Only by understanding the basic biological processes at work in the oceans can humans live sustainably on earth.

## 2

#### The reason morality exists is to regulate our actions towards others. If any moral code is not motivational then there is no reason to do what is right and that code merely fails to escape the skeptical conclusion. Motivational externalism collapses into Internalism.

**Joyce 1**, Richard (Professor of Philosophy at Victoria University Wellington, New Zealand). The Myth of Morality. 2001. [Bracketed for grammatical clarity]

Back to the [Suppose] external reason[s]. Suppose it were claimed, instead, that I have a reason to refrain from drinking the coffee because it is tapu and must not be touched. This reason claim will be urged regardless of what I may say about my indifference to tapu, or my citing of nihilistic desires to tempt the hand of fate. [r]egardless of my desires (it is claimed) I ought not drink - l have a reason not to drink. But how could that reason ever explain any action of mine? Could the external reason even explain my [action] from drinking? Clearly, in order to explain it the external reason must have some causally efficacious role [in] among the antecedents of the action (in this case, an omission) — l must have. in some manner. "internalized" it. The only possibility, it would seem, consistent with its being an external reason, is that I believe the external reason claim [but] : I believe that the coffee is tapu. There's no doubting that such a belief can play a role in explaining actions - including my refraining from drinking the coffee. The question is whether the **belief alone can[not] produce action**, to which the correct answer is “No.” A very familiar and eminently sensible view says that **in** order to explain an action the belief must couple with desires (such that those same desires had in the absence of the belief would not have resulted in the action). And this seems correct: if I believe that the coffee is [bad] tapu but really just don’t care about that, then I will not refrain from drinking it. So in order for the belief to explain action it must couple with [desire] elements - but in that case the putative external reason collapses into an internal one.3

#### Additionally, agents can only be motivated by their own desires; not externally because A] Empirical uncertainty- evil demon could deceive us, dreaming, simulation, and inability to know others’ experience make externalism an unreliable B] Because individuals have unlimited wants and those are not communicated C] Egoism- we only care about our own desires as individuals are self-interested and don’t care about helping others, even if we did know how to help.

#### Only a contractarian system that derives principles of mutual restraint from individuals’ self-interest account for this fact because contractarian principles are necessarily in the interest of all parties involved because they wouldn’t constrain their action against their will.

**Gauthier 86** Gauthier, David P. *Morals by Agreement*. Oxford: Clarendon, 1986. Print.

Moral principles are introduced as the objects of full voluntary ex ante agreement among rational persons. Su**ch agreement is hypothetical,** in supposing a pre-moral context for the adoption of moral rules and practices. **But the parties to agreement are real,** determinate individuals, **distinguished by their** capacities, **situations, and concerns.** In so far as **[**Since] they would agree to constraints on their choices, restraining their pursuit of their own interests, they acknowledge a distinction between what they may and may not do. As rational persons understanding the structure of their interaction, they recognize for mutual constraint, and so for a moral dimension in their affairs.

#### Additionally, self-interest is determined at the time of the original decision to rise to a norm of mutual self-restraint. For example, I might say that eating ice cream is in my self-interest because I’m hungry even if it will lead to extinction somehow in the future.

#### Thus, the standard is consistency with contractarian principles of mutual restraint, defined as the principles by which individuals constrain their actions with the belief that doing so would serve their self-interest.

#### Prefer additionally:

#### 1] Consent- contractarianism is based on consent which determines what qualifies as a net good or harm. Moral theories must be based in consent otherwise actions could never be determinate.

#### 2] Regress- we can always question morality- authority begs the question of why their assessment ought be preferred over other assessments- Contractarianism avoids this by allowing individuals to construct conceptions of the good based on a rational restriction of their future actions.

#### 3] Performativity- You agree to 4 minutes of prep and if you tried to go over the judges would down you- their very performance justifies the NC framework and proves it collapses.

### Offense

#### Negate:

#### 1] Affs violate a host of existing private contracts.

Sauer 21 [Hans; Deputy General Counsel and Vice President for Intellectual Property for the Biotechnology Innovation Organization (BIO), a major trade association representing more than 1,000 biotechnology companies from the medical, agricultural, environmental, and industrial sectors. At BIO, he advises the organization’s board of directors, amicus committee, and various staff committees on patent and other intellectual-property-related matters. Before taking his current position at BIO in 2006, he was chief patent counsel for MGI Pharma Inc. in Bloomington, MN, and senior patent counsel for Guilford Pharmaceuticals Inc. in Baltimore, MD. Mr. Sauer holds a M.S. degree in biology from the University of Ulm in his native Germany, a Ph.D. in neuroscience from the University of Lund, Sweden, and a J.D. degree from Georgetown University Law Center, where he serves as adjunct professor; “Waiving IP Rights During Times of COVID: A ‘False Good Idea’,” IP Watch Dog; 4/19/21; <https://www.ipwatchdog.com/2021/04/19/waiving-ip-rights-during-times-of-covid-a-false-good-idea/id=132399/>] Justin

One wonders whether Congressional proponents of the TRIPS Waiver have given any thought as to how it could be implemented in U.S. law. There is no mechanism in U.S. law for simply waiving vested IP rights. Amendments to the federal patent, copyright, food and drug, and other federal statutes would need to be attempted; trade secret protections under 50 state laws overridden; and the waiver’s interference with the IP and confidentiality provisions of myriad existing private contracts would need to be sorted out. As a result, the Federal Government would have to assume unforeseeable and potentially colossal financial liability. And because the waiver is intended for the benefit of foreign developing nations, the legality of any attempt at U.S. domestic implementation would be doubtful, as Congress has no authority to expropriate U.S. property to benefit foreign countries. It is of course possible that Congressional proponents of the waiver are merely engaging in virtue-signaling, without any intention of ever implementing anything. But nonetheless, the waiver is certain to invite similar legislative train wrecks in other countries that aspire to the rule of law, and it is perplexing how little forethought seems to have gone into the proposal.

#### 2] Forecloses the ability for future contracts.

Hilty et al 21 [Reto Hilty Director at the Max Planck Institute for Innovation and Competition and a professor at the University of Zurich Pedro Henrique D. Batista Doctoral student and Junior Research Fellow at the Max Planck Institute for Innovation and Competition Suelen Carls Senior Research Fellow at the Max Planck Institute for Innovation and Competition Daria Kim Senior Research Fellow at the Max Planck Institute for Innovation and Competition Matthias Lamping Senior Research Fellow at the Max Planck Institute for Innovation and Competition Peter R. Slowinski Doctoral student and Junior Research Fellow at the Max Planck Institute for Innovation and Competition; “10 Arguments against a Waiver of Intellectual Property Rights,” Oxford Law; 6/29/21; <https://www.law.ox.ac.uk/business-law-blog/blog/2021/06/10-arguments-against-waiver-intellectual-property-rights>] Justin

2. Intellectual property rights are the **basis for collaborations and contracts** The **development cycle of the new mRNA and vector vaccines**—from the provision of the technological basis to safety studies and marketing authorisation—is **tremendously multifaceted**. Nevertheless, throughout the development, production and distribution of vaccines against Covid-19, cooperation has reached an **unprecedented** level—despite the typically fierce **competition in the biopharmaceutical sector**. Intellectual property rights and particularly patents are normally the basis for such cooperation; they provide assurance that contracts will be **fulfilled. Even a temporary waiver** of these rights may therefore have **detrimental consequences for the willingness to cooperate**.

## 3

#### Permissibility and presumption negate – a. the resolution indicates the affirmative has to prove an obligation, and permissibility would deny the existence of an obligation b. Statements are more often false than true because any part can be false so negate because the aff is probably false

#### The aff burden is to prove that the resolutional statement is logical, and the reciprocal neg burden is to prove that the resolutional statement is illogical.

#### Prefer:

#### 1. Text – Oxford Dictionary defines ought as “used to indicate something that is probable.”

[https://en.oxforddictionaries.com/definition/ought //](https://en.oxforddictionaries.com/definition/ought%20//)Massa

#### Ought is “used to express logical consequence” as defined by Merriam-Webster

(<http://www.merriam-webster.com/dictionary/ought>) //Massa

#### 2. Debatability – a) my interp means debates focus on empirics about squo trends rather than irresolvable abstract principles that’ve been argued for years b) Moral oughts cannot guide action.

**Gray,** Grey, JW. "The Is/Ought Gap: How Do We Get "Ought" from "Is?"" *Ethical Realism*. N.p., 19 July 2011. Web. 28 Oct. 2015. //Massa

**The is/ought gap is a problem in moral philosophy where what is the case and what ought to be the case seem quite different, and it presents itself as the following question** to David Hume: **How do we *know* what morally ought to be the case from what is the case?** Hume posed the question in A Treatise of Human Nature Book III Part I Section I: In **every system of morality**, which I have hitherto met with, I have always remark’d that the author proceeds for some time in the ordinary way of reasoning, and establishes the being of a God, or makes observations concerning human affairs, when of a sudden I am surpriz’d to find, that instead of the usual copulations of propositions, is and is not, I meet with no proposition that is not connected with an ought, or an ought not. This change **is imperceptible**; but is, however, of the last consequence. **For as this ought**, or ought not, **expresses some new relation** or affirmation, ‘tis necessary that it shou’d be observ’d and explain’d; and at the same time that a reason shou’d be given, **for what seems altogether inconceivable**, how this new relation can be a deduction from others, which are entirely different from it. It is here that Hume points out that **philosophers argue about** various **nonmoral facts, then somehow conclude what ought to be the case** (or what people ought to do) **based on** those facts (about **what is the case**). **For example, we might find out that arsenic is poisonous and conclude that we ought not consume it. But we need to know how nonmoral facts can lead to moral conclusions. These two things seem unrelated. The is/ought gap [isn’t]** doesn’t seem like **a problem for nonmoral oughts**—what we ought to do to accomplish our goals, fulfill our desires, or maintain our commitments. For example, we could say, “If you want to be healthy, you ought not consume arsenic.” However, it might be morally wrong to consume arsenic. If it is, we have some more explaining to do.

#### 4. Neg definition choice – The aff should have defined ought in the 1ac as their value, by not doing so they have forfeited their right to read a new definition – kills 1NC strategy since I premised my engagement on a lack of your definition.

#### [1] Inherency – either a) the aff is non-inherent and you vote neg on presumption or b) it is and it isn’t logically going to happen.

#### [2] Intellectual is defined as “possessing or showing intellect or mental compacity” (Dictionary.com) but property cant possess intellect so the resolutions incoherent

## 4

#### Interpretation: “medicines” is a generic bare plural. The aff may not defend that member nations of the World Trade Organization ought to reduce intellectual property protections for a medicine or subset of medicines.

Nebel 19. [Jake Nebel is an assistant professor of philosophy at the University of Southern California and executive director of Victory Briefs. He writes a lot of this stuff lol – duh.] “Genericity on the Standardized Tests Resolution.” Vbriefly. August 12, 2019. <https://www.vbriefly.com/2019/08/12/genericity-on-the-standardized-tests-resolution/?fbclid=IwAR0hUkKdDzHWrNeqEVI7m59pwsnmqLl490n4uRLQTe7bWmWDO_avWCNzi14> TG

Both distinctions are important. Generic resolutions can’t be affirmed by specifying particular instances. But, since generics tolerate exceptions, plan-inclusive counterplans (PICs) do not negate generic resolutions.

Bare plurals are typically used to express generic generalizations. But there are two important things to keep in mind. First, generic generalizations are also often expressed via other means (e.g., definite singulars, indefinite singulars, and bare singulars). Second, and more importantly for present purposes, bare plurals can also be used to express existential generalizations. For example, “Birds are singing outside my window” is true just in case there are some birds singing outside my window; it doesn’t require birds in general to be singing outside my window.

So, what about “colleges and universities,” “standardized tests,” and “undergraduate admissions decisions”? Are they generic or existential bare plurals? On other topics I have taken great pains to point out that their bare plurals are generic—because, well, they are. On this topic, though, I think the answer is a bit more nuanced. Let’s see why.

“Colleges and universities” is a generic bare plural. I don’t think this claim should require any argument, when you think about it, but here are a few reasons.

First, ask yourself, honestly, whether the following speech sounds good to you: “Eight colleges and universities—namely, those in the Ivy League—ought not consider standardized tests in undergraduate admissions decisions. Maybe other colleges and universities ought to consider them, but not the Ivies. Therefore, in the United States, colleges and universities ought not consider standardized tests in undergraduate admissions decisions.” That is obviously not a valid argument: the conclusion does not follow. Anyone who sincerely believes that it is valid argument is, to be charitable, deeply confused. But the inference above would be good if “colleges and universities” in the resolution were existential. By way of contrast: “Eight birds are singing outside my window. Maybe lots of birds aren’t singing outside my window, but eight birds are. Therefore, birds are singing outside my window.” Since the bare plural “birds” in the conclusion gets an existential reading, the conclusion follows from the premise that eight birds are singing outside my window: “eight” entails “some.” If the resolution were existential with respect to “colleges and universities,” then the Ivy League argument above would be a valid inference. Since it’s not a valid inference, “colleges and universities” must be a generic bare plural.

Second, “colleges and universities” fails the [upward-entailment test](https://plato.stanford.edu/entries/generics/#IsolGeneInte) for existential uses of bare plurals. Consider the sentence, “Lima beans are on my plate.” This sentence expresses an existential statement that is true just in case there are some lima beans on my plate. One test of this is that it entails the more general sentence, “Beans are on my plate.” Now consider the sentence, “Colleges and universities ought not consider the SAT.” (To isolate “colleges and universities,” I’ve eliminated the other bare plurals in the resolution; it cannot plausibly be generic in the isolated case but existential in the resolution.) This sentence does not entail the more general statement that educational institutions ought not consider the SAT. This shows that “colleges and universities” is generic, because it fails the upward-entailment test for existential bare plurals.

Third, “colleges and universities” fails the adverb of quantification test for existential bare plurals. Consider the sentence, “Dogs are barking outside my window.” This sentence expresses an existential statement that is true just in case there are some dogs barking outside my window. One test of this appeals to the drastic change of meaning caused by inserting any adverb of quantification (e.g., always, sometimes, generally, often, seldom, never, ever). You cannot add any such adverb into the sentence without drastically changing its meaning. To apply this test to the resolution, let’s again isolate the bare plural subject: “Colleges and universities ought not consider the SAT.” Adding generally (“Colleges and universitiesz generally ought not consider the SAT”) or ever (“Colleges and universities ought not ever consider the SAT”) result in comparatively minor changes of meaning. (Note that this test doesn’t require there to be no change of meaning and doesn’t have to work for every adverb of quantification.) This strongly suggests what we already know: that “colleges and universities” is generic rather than existential in the resolution.

#### It applies to “medicines” – 1] upward entailment test – “member nations of the World Trade Organization ought to reduce intellectual property protections for medicines” doesn’t entail that member nations of the WTO ought to reduce IPP for drugs because it doesn’t prove that marijuana protections should be reduced 2] adverb test – adding “always” to the res doesn’t substantially change its meaning because reduce is permanent.

#### Violation: They spec \_\_\_\_\_\_

#### Standards:

#### [1] precision – the counter-interp justifies them arbitrarily doing away with random words in the resolution which decks negative ground and preparation because the aff is no longer bounded by the resolution. Independent voter for jurisdiction – the judge doesn’t have the jurisdiction to vote aff if there wasn’t a legitimate aff.

#### [2] Limits and ground – their model allows affs to defend anything from Covid vaccines to HIV drugs to Insulin— there's no universal DA since each has different functions and political implications — that explodes neg prep and leads to random medicine of the week affs which makes cutting stable neg links impossible — limits key to reciprocal engagement since they create a caselist for neg prep and it takes out ground like DAs to certain medicines which are some of the few neg generics when affs spec medicines.

#### [3] TVA solves – you could’ve read your plan as an advantage under a whole res advocacy.

#### Fairness – debate is a competitive activity that requires fairness for objective evaluation. Outweighs because it’s the only intrinsic part of debate – all other rules can be debated over but rely on some conception of fairness to be justified.

#### Drop the debater – a] deter future abuse and b] set better norms for debate.

#### Competing interps – [a] reasonability is arbitrary and encourages judge intervention since there’s no clear norm, [b] it creates a race to the top where we create the best possible norms for debate.

#### No RVIs – a] illogical, you don’t win for proving that you meet the burden of being fair, logic outweighs since it’s a prerequisite for evaluating any other argument, b] RVIs incentivize baiting theory and prepping it out which leads to maximally abusive practices

## Case

#### Extinction is inevitable from future technology — nanotech, our simulation gets shut down, AI, biotech, particle accelerators, and black swans

Bruce **Sterling**, 6-1-20**18**, "When Nick Bostrom says “Bang”," WIRED, https://www.wired.com/beyond-the-beyond/2018/06/nick-bostrom-says-bang/

4.1 Deliberate misuse of nanotechnology In a mature form, molecular nanotechnology will enable the construction of bacterium-scale self-replicating mechanical robots that can feed on dirt or other organic matter [22-25]. Such replicators could eat up the biosphere or destroy it by other means such as by poisoning it, burning it, or blocking out sunlight. A person of malicious intent in possession of this technology might cause the extinction of intelligent life on Earth by releasing such nanobots into the environment.[9] The technology to produce a destructive nanobot seems considerably easier to develop than the technology to create an effective defense against such an attack (a global nanotech immune system, an “active shield” [23]). It is therefore likely that there will be a period of vulnerability during which this technology must be prevented from coming into the wrong hands. Yet the technology could prove hard to regulate, since it doesn’t require rare radioactive isotopes or large, easily identifiable manufacturing plants, as does production of nuclear weapons [23]. Even if effective defenses against a limited nanotech attack are developed before dangerous replicators are designed and acquired by suicidal regimes or terrorists, there will still be the danger of an arms race between states possessing nanotechnology. It has been argued [26] that molecular manufacturing would lead to both arms race instability and crisis instability, to a higher degree than was the case with nuclear weapons. Arms race instability means that there would be dominant incentives for each competitor to escalate its armaments, leading to a runaway arms race. Crisis instability means that there would be dominant incentives for striking first. Two roughly balanced rivals acquiring nanotechnology would, on this view, begin a massive buildup of armaments and weapons development programs that would continue until a crisis occurs and war breaks out, potentially causing global terminal destruction. That the arms race could have been predicted is no guarantee that an international security system will be created ahead of time to prevent this disaster from happening. The nuclear arms race between the US and the USSR was predicted but occurred nevertheless. 4.2 Nuclear holocaust[winter] The US and Russia still have huge stockpiles of nuclear weapons. But would an all-out nuclear war really exterminate humankind? Note that: (i) For there to be an existential risk it suffices that we can’t be sure that it wouldn’t. (ii) The climatic effects of a large nuclear war are not well known (there is the possibility of a nuclear winter). (iii) Future arms races between other nations cannot be ruled out and these could lead to even greater arsenals than those present at the height of the Cold War. The world’s supply of plutonium has been increasing steadily to about two thousand tons, some ten times as much as remains tied up in warheads ([9], p. 26). (iv) Even if some humans survive the short-term effects of a nuclear war, it could lead to the collapse of civilization. A human race living under stone-age conditions may or may not be more resilient to extinction than other animal species. 4.3 We’re living in a simulation and it gets shut down A case can be made that the hypothesis that we are living in a computer simulation should be given a significant probability [27]. The basic idea behind this so-called “Simulation argument” is that vast amounts of computing power may become available in the future (see e.g. [28,29]), and that it could be used, among other things, to run large numbers of fine-grained simulations of past human civilizations. Under some not-too-implausible assumptions, the result can be that almost all minds like ours are simulated minds, and that we should therefore assign a significant probability to being such computer-emulated minds rather than the (subjectively indistinguishable) minds of originally evolved creatures. And if we are, we suffer the risk that the simulation may be shut down at any time. A decision to terminate our simulation may be prompted by our actions or by exogenous factors. While to some it may seem frivolous to list such a radical or “philosophical” hypothesis next the concrete threat of nuclear holocaust, we must seek to base these evaluations on reasons rather than untutored intuition. Until a refutation appears of the argument presented in [27], it would intellectually dishonest to neglect to mention simulation-shutdown as a potential extinction mode. 4.4 Badly programmed superintelligence When we create the first superintelligent entity [28-34], we might make a mistake and give it goals that lead it to annihilate humankind, assuming its enormous intellectual advantage gives it the power to do so. For example, we could mistakenly elevate a subgoal to the status of a supergoal. We tell it to solve a mathematical problem, and it complies by turning all the matter in the solar system into a giant calculating device, in the process killing the person who asked the question. (For further analysis of this, see [35].) 4.5 Genetically engineered biological agent With the fabulous advances in genetic technology currently taking place, it may become possible for a tyrant, terrorist, or ~~lunatic~~ to create a doomsday virus, an organism that combines long latency with high virulence and mortality [36]. Dangerous viruses can even be spawned unintentionally, as Australian researchers recently demonstrated when they created a modified mousepox virus with 100% mortality while trying to design a contraceptive virus for mice for use in pest control [37]. While this particular virus doesn’t affect humans, it is suspected that an analogous alteration would increase the mortality of the human smallpox virus. What underscores the future hazard here is that the research was quickly published in the open scientific literature [38]. It is hard to see how information generated in open biotech research programs could be contained no matter how grave the potential danger that it poses; and the same holds for research in nanotechnology. Genetic medicine will also lead to better cures and vaccines, but there is no guarantee that defense will always keep pace with offense. (Even the accidentally created mousepox virus had a 50% mortality rate on vaccinated mice.) Eventually, worry about biological weapons may be put to rest through the development of nanomedicine, but while nanotechnology has enormous long-term potential for medicine [39] it carries its own hazards. 4.6 Accidental misuse of nanotechnology (“gray goo”) The possibility of accidents can never be completely ruled out. However, there are many ways of making sure, through responsible engineering practices, that species-destroying accidents do not occur. One could avoid using self-replication; one could make nanobots dependent on some rare feedstock chemical that doesn’t exist in the wild; one could confine them to sealed environments; one could design them in such a way that any mutation was overwhelmingly likely to cause a nanobot to completely cease to function [40]. Accidental misuse is therefore a smaller concern than malicious misuse [23,25,41]. However, the distinction between the accidental and the deliberate can become blurred. While “in principle” it seems possible to make terminal nanotechnological accidents extremely improbable, the actual circumstances may not permit this ideal level of security to be realized. Compare nanotechnology with nuclear technology. From an engineering perspective, it is of course perfectly possible to use nuclear technology only for peaceful purposes such as nuclear reactors, which have a zero chance of destroying the whole planet. Yet in practice it may be very hard to avoid nuclear technology also being used to build nuclear weapons, leading to an arms race. With large nuclear arsenals on hair-trigger alert, there is inevitably a significant risk of accidental war. The same can happen with nanotechnology: it may be pressed into serving military objectives in a way that carries unavoidable risks of serious accidents. In some situations it can even be strategically advantageous to deliberately make one’s technology or control systems risky, for example in order to make a “threat that leaves something to chance” [42]. 4.7 Something unforeseen We need a catch-all category. It would be foolish to be confident that we have already imagined and anticipated all significant risks. Future technological or scientific developments may very well reveal novel ways of destroying the world. Some foreseen hazards (hence not members of the current category) which have been excluded from the list of bangs on grounds that they seem too unlikely to cause a global terminal disaster are: solar flares, supernovae, black hole explosions or mergers, gamma-ray bursts, galactic center outbursts, supervolcanos, loss of biodiversity, buildup of air pollution, gradual loss of human fertility, and various religious doomsday scenarios. The hypothesis that we will one day become “illuminated” and commit collective suicide or stop reproducing, as supporters of VHEMT (The Voluntary Human Extinction Movement) hope [43], appears unlikely. If it really were better not to exist (as Silenus told king Midas in the Greek myth, and as Arthur Schopenhauer argued [44] although for reasons specific to his philosophical system he didn’t advocate suicide), then we should not count this scenario as an existential disaster. The assumption that it is not worse to be alive should be regarded as an implicit assumption in the definition of Bangs. Erroneous collective suicide is an existential risk albeit one whose probability seems extremely slight. (For more on the ethics of human extinction, see chapter 4 of [9].) 4.8 Physics disasters The Manhattan Project bomb-builders’ concern about an A-bomb-derived atmospheric conflagration has contemporary analogues. There have been speculations that future high-energy particle accelerator experiments may cause a breakdown of a metastable vacuum state that our part of the cosmos might be in, converting it into a “true” vacuum of lower energy density [45]. This would result in an expanding bubble of total destruction that would sweep through the galaxy and beyond at the speed of light, tearing all matter apart as it proceeds. Another conceivability is that accelerator experiments might produce negatively charged stable “strangelets” (a hypothetical form of nuclear matter) or create a mini black hole that would sink to the center of the Earth and start accreting the rest of the planet [46]. These outcomes seem to be impossible given our best current physical theories. But the reason we do the experiments is precisely that we don’t really know what will happen. A more reassuring argument is that the energy densities attained in present day accelerators are far lower than those that occur naturally in collisions between cosmic rays [46,47]. It’s possible, however, that factors other than energy density are relevant for these hypothetical processes, and that those factors will be brought together in novel ways in future experiments. The main reason for concern in the “physics disasters” category is the meta-level observation that discoveries of all sorts of weird physical phenomena are made all the time, so even if right now all the particular physics disasters we have conceived of were absurdly improbable or impossible, there could be other more realistic failure-modes waiting to be uncovered. The ones listed here are merely illustrations of the general case.

#### The transition to superintelligence is rapid, opaque, and would cause universal extinction

James Daniel **Miller 18**. Based at Smith College, South Deerfield, Massachusetts. 10/11/2018. “When Two Existential Risks Are Better than One.” Foresight. Crossref, doi:10.1108/FS-04-2018-0038.

2. The dangers of unfriendly powerful artificial general intelligence Unlike with whatever wetware runs the human brain, it would be relatively easy to make changes to a PAGI’s software. PAGI could even make changes to itself. Such selfmodification could possibly allow PAGI to undergo an intelligence explosion where it figures out how to improve its own intelligence, then, as it gets smarter, it figures out new ways to improve its intelligence. It has been theorized that through recursive self-improvement a PAGI could go from being a bit smarter than humans to becoming a computer superintelligence in a matter of days (Good, 1965; Yudkowsky, 2008). If our understanding of the laws of physics is correct, the universe contains a limited amount of free energy, and this free energy is necessary to do any kind of work and most types of computing. Consequently, it has been theorized that most types of computer superintelligences would have an instrumental goal of gathering as much free energy as possible to further whatever ultimate goals they had (Omohundro, 2008). Humanity’s continued existence uses free energy. Consequently, if a PAGI did not have promoting human welfare as a goal, it would likely see humanity’s continuing existence as rival to its terminal values. A PAGI that wanted to maximize its understanding of, say, chess would further this end by exterminating mankind and using the atoms in our bodies to make chess computing hardware. A PAGI that wanted to maximize the number of paperclips in the universe would likewise kill us, not out of malice, but to align the atoms in our bodies with its objective. The term “paperclip maximizer” has come to mean a PAGI that seeks to use all the resources it can get for an objective that most humans would not consider worthwhile (Arbital Contributors, 2017). A PAGI that was smarter than humans, but not yet smart enough to take over the world, would have an incentive to hide its abilities and intentions from us if it predicted that we would turn the PAGI off if it scared us. Consequently, the PAGI might appear friendly weak, and unambitious right until it launches a surprise devastating attack on us, by taking what has been called a “treacherous turn” (Bostrom, 2014, pp. 116-119).

#### Rigorous climate simulations prove that hydrophilic black carbon would cause to atmospheric precipitation – results in a rainout effect that quickly reverses nuclear cooling

Reisner et al. 18 (Jon Reisner – Climate and atmospheric scientist at the Los Alamos National Laboratory. Gennaro D’Angelo – Climate scientist at the Los Alamos National Laboratory, Research scientist at the SETI institute, Associate specialist at the University of California, Santa Cruz, NASA Postdoctoral Fellow at the NASA Ames Research Center, UKAFF Fellow at the University of Exeter. Eunmo Koo - Scientist at Applied Terrestrial, Energy, and Atmospheric Modeling (ATEAM) Team, in Computational Earth Science Group (EES-16) in Earth and Environmental Sciences Division and Co-Lead of Parallel Computing Summer Research Internship (PCSRI) program at the Los Alamos National Laboratory, former Staff research associate at UC Berkeley. Wesley Even - Computational scientist in the Computational Physics and Methods Group at Los Alamos National Laboratory. Matthew Hecht – Atmospheric scientist at the Los Alamos National Laboratory. Elizabeth Hunke - Lead developer for the Los Alamos Sea Ice Model (CICE) at the Los Alamos National Laboratory responsible for development and incorporation of new parameterizations, model testing and validation, computational performance, documentation, and consultation with external model users on all aspects of sea ice modeling, including interfacing with global climate and earth system models. Darin Comeau – Climate scientist at the Los Alamos National Laboratory. Randy Bos - Project leader at the Los Alamos National Laboratory, former Weapons Effects program manager at Tech-Source. James Cooley – Computational scientist at the Los Alamos National Laboratory specializing in weapons physics, emergency response, and computational physics. <MKIM> “Climate impact of a regional nuclear weapons exchange:An improved assessment based on detailed source calculations”. 3/16/18. DOA: 7/13/19. <https://agupubs.onlinelibrary.wiley.com/doi/full/10.1002/2017JD027331>)

\*BC = Black Carbon

The no-rubble simulation produces a significantly more intense fire, with more fire spread, and consequently a significantly stronger plume with larger amounts of BC reaching into the upper atmosphere than the simulation with rubble, illustrated in Figure 5. While the no-rubble simulation **represents the worst-case scenario** involving vigorous fire activity, **only a relatively small amount of carbon makes its way into the stratosphere** during the course of the simulation. But while small compared to the surface BC mass, stratospheric BC amounts from the current simulations are significantly higher than what would be expected from burning vegetation such as trees (Heilman et al., 2014), e.g., the higher energy density of the building fuels and the initial fluence from the weapon produce an intense response within HIGRAD with initial updrafts of order 100 m/s in the lower troposphere. Or, in comparison to a mass fire, wildfires will burn only a small amount of fuel in the corresponding time period (roughly 10 minutes) that a nuclear weapon fluence can effectively ignite a large area of fuel producing an impressive atmospheric response. Figure 6 shows vertical profiles of BC multiplied by 100 (number of cities involved in the exchange) from the two simulations. The total amount of BC produced is in line with previous estimates (about 3.69 Tg from no-rubble simulation); however, the majority of BC resides **below the stratosphere** (3.46 Tg below 12 km) and can be **readily impacted by scavenging from precipitation** either via pyro-cumulonimbus produced by the fire itself (not modeled) or other synoptic weather systems. While the impact on climate of these more realistic profiles will be explored in the next section, it should be mentioned that **these estimates are** still **at the high end**, considering the inherent simplifications in the combustion model that lead to **overestimating BC production**. 3.3 Climate Results Long-term climatic effects critically depend on the initial injection height of the soot, with larger quantities reaching the upper troposphere/lower stratosphere inducing a greater cooling impact because of longer residence times (Robock et al., 2007a). Absorption of solar radiation by the BC aerosol and its subsequent radiative cooling tends to heat the surrounding air, driving an initial upward diffusion of the soot plumes, an effect that depends on the initial aerosol concentrations. **Mixing and sedimentation** tend to **reduce this process**, and low altitude emissions are also significantly impacted by precipitation if aging of the BC aerosol occurs on sufficiently rapid timescales. But once at stratospheric altitudes, aerosol dilution via coagulation is hindered by low particulate concentrations (e.g., Robock et al., 2007a) and lofting to much higher altitudes is inhibited by gravitational settling in the low-density air (Stenke et al., 2013), resulting in more stable BC concentrations over long times. Of the initial BC mass released in the atmosphere, most of which is emitted below 9 km, **70% rains out within the first month** and 78%, or about 2.9 Tg, is removed within the first two months (Figure 7, solid line), with the remainder (about 0.8 Tg, dashed line) being transported above about 12 km (200 hPa) within the first week. This outcome differs from the findings of, e.g., Stenke et al. (2013, their high BC-load cases) and Mills et al. (2014), who found that most of the BC mass (between 60 and 70%) is lifted in the stratosphere within the first couple of weeks. This can also be seen in Figure 8 (red lines) and in Figure 9, which include results from our calculation with the initial BC distribution from Mills et al. (2014). In that case, only 30% of the initial BC mass rains out in the troposphere during the first two weeks after the exchange, with the remainder rising to the stratosphere. In the study of Mills et al. (2008) this percentage is somewhat smaller, about 20%, and smaller still in the experiments of Robock et al. (2007a) in which the soot is initially emitted in the upper troposphere or higher. In Figure 7, the e-folding timescale for the removal of tropospheric soot, here interpreted as the time required for an initial drop of a factor e, is about one week. This result compares favorably with the “LT” experiment of Robock et al. (2007a), considering 5 Tg of BC released in the lower troposphere, in which 50% of the aerosols are removed within two weeks. By contrast, the initial e-folding timescale for the removal of stratospheric soot in Figure 8 is about 4.2 years (blue solid line), compared to about 8.4 years for the calculation using Mills et al. (2014) initial BC emission (red solid line). The removal timescale from our forced ensemble simulations is close to those obtained by Mills et al. (2008) in their 1 Tg experiment, by Robock et al. (2007a) in their experiment “UT 1 Tg”, and © 2018 American Geophysical Union. All rights reserved. by Stenke et al. (2013) in their experiment “Exp1”, in all of which 1 Tg of soot was emitted in the atmosphere in the aftermath of the exchange. Notably, the e-folding timescale for the decline of the BC mass in Figure 8 (blue solid line) is also close to the value of about 4 years quoted by Pausata et al. (2016) for their long-term “intermediate” scenario. In that scenario, which is also based on 5 Tg of soot initially distributed as in Mills et al. (2014), the factor-of2 shorter residence time of the aerosols is caused by particle growth via coagulation of BC with organic carbon. Figure 9 shows the BC mass-mixing ratio, horizontally averaged over the globe, as a function of atmospheric pressure (height) and time. The BC distributions used in our simulations imply that the upward transport of particles is substantially less efficient compared to the case in which 5 Tg of BC is directly injected into the upper troposphere. The semiannual cycle of lofting and sinking of the aerosols is associated with atmospheric heating and cooling during the solstice in each hemisphere (Robock et al., 2007a). During the first year, the oscillation amplitude in our forced ensemble simulations is particularly large during the summer solstice, compared to that during the winter solstice (see bottom panel of Figure 9), because of the higher soot concentrations in the Northern Hemisphere, as can be seen in Figure 11 (see also left panel of Figure 12). Comparing the top and bottom panels of Figure 9, the BC reaches the highest altitudes during the first year in both cases, but the concentrations at 0.1 hPa in the top panel can be 200 times as large. Qualitatively, the difference can be understood in terms of the air temperature increase caused by BC radiation emission, which is several tens of kelvin degrees in the simulations of Robock et al. (2007a, see their Figure 4), Mills et al. (2008, see their Figure 5), Stenke et al. (2013, see high-load cases in their Figure 4), Mills et al. (2014, see their Figure 7), and Pausata et al. (2016, see one-day emission cases in their Figure 1), due to high BC concentrations, but it amounts to only about 10 K in our forced ensemble simulations, as illustrated in Figure 10. Results similar to those presented in Figure 10 were obtained from the experiment “Exp1” performed by Stenke et al. (2013, see their Figure 4). **In that scenario as well, somewhat less that 1 Tg of BC remained in the atmosphere after the initial rainout**. As mentioned before, the BC aerosol that remains in the atmosphere, lifted to stratospheric heights by the rising soot plumes, undergoes sedimentation over a timescale of several years (Figures 8 and 9). This mass represents the effective amount of BC that can force climatic changes over multi-year timescales. In the forced ensemble simulations, it is about 0.8 Tg after the initial rainout, whereas it is about 3.4 Tg in the simulation with an initial soot distribution as in Mills et al. (2014). Our more realistic source simulation involves the worstcase assumption of no-rubble (along with other assumptions) and hence serves as an upper bound for the impact on climate. As mentioned above and further discussed below, our scenario induces perturbations on the climate system similar to those found in previous studies in which the climatic response was driven by roughly 1 Tg of soot rising to stratospheric heights following the exchange. Figure 11 illustrates the vertically integrated mass-mixing ratio of BC over the globe, at various times after the exchange for the simulation using the initial BC distribution of Mills et al. (2014, upper panels) and as an average from the forced ensemble members (lower panels). All simulations predict enhanced concentrations at high latitudes during the first year after the exchange. In the cases shown in the top panels, however, these high concentrations persist for several years (see also Figure 1 of Mills et al., 2014), whereas the forced ensemble simulations indicate that the BC concentration starts to decline after the first year. In fact, in the simulation represented in the top panels, mass-mixing ratios larger than about 1 kg of BC © 2018 American Geophysical Union. All rights reserved. per Tg of air persist for well over 10 years after the exchange, whereas they only last for 3 years in our forced simulations (compare top and middle panels of Figure 9). After the first year, values drop below 3 kg BC/Tg air, whereas it takes about 8 years to reach these values in the simulation in the top panels (see also Robock et al., 2007a). Over crop-producing, midlatitude regions in the Northern Hemisphere, the BC loading is reduced from more than 0.8 kg BC/Tg air in the simulation in the top panels to 0.2-0.4 kg BC/Tg air in our forced simulations (see middle and right panels). The more rapid clearing of the atmosphere in the forced ensemble is also signaled by the soot optical depth in the visible radiation spectrum, which drops below values of 0.03 toward the second half of the first year at mid latitudes in the Northern Hemisphere, and everywhere on the globe after about 2.5 years (without never attaining this value in the Southern Hemisphere). In contrast, the soot optical depth in the calculation shown in the top panels of Figure 11 becomes smaller than 0.03 everywhere only after about 10 years. The two cases show a similar tendency, in that the BC optical depth is typically lower between latitudes 30º S-30º N than it is at other latitudes. This behavior is associated to the persistence of stratospheric soot toward high-latitudes and the Arctic/Antarctic regions, as illustrated by the zonally-averaged, column-integrated mass-mixing ratio of the BC in Figure 12 for both the forced ensemble simulations (left panel) and the simulation with an initial 5 Tg BC emission in the upper troposphere (right panel). The spread in the globally averaged (near) surface temperature of the atmosphere, from the control (left panel) and forced (right panel) ensembles, is displayed in Figure 13. For each month, the plots show the largest variations (i.e., maximum and minimum values), within each ensemble of values obtained for that month, relative to the mean value of that month. The plot also shows yearly-averaged data (thinner lines). The spread is comparable in the control and forced ensembles, with average values calculated over the 33-years run length of 0.4-0.5 K. This spread is also similar to the internal variability of the globally averaged surface temperature quoted for the NCAR Large Ensemble Community Project (Kay et al., 2015). These results imply that surface air temperature differences, between forced and control simulations, which lie within the spread may not be distinguished from effects due to internal variability of the two simulation ensembles. Figure 14 shows the difference in the globally averaged surface temperature of the atmosphere (top panel), net solar radiation flux at surface (middle panel), and precipitation rate (bottom panel), computed as the (forced minus control) difference in ensemble mean values. The sum of standard deviations from each ensemble is shaded. Differences are qualitatively significant over the first few years, when the anomalies lie near or outside the total standard deviation. Inside the shaded region, differences may not be distinguished from those arising from the internal variability of one or both ensembles. The surface solar flux (middle panel) is the quantity that appears most affected by the BC emission, with qualitatively significant differences persisting for about 5 years. The precipitation rate (bottom panel) is instead affected only at the very beginning of the simulations. The red lines in all panels show the results from the simulation applying the initial BC distribution of Mills et al. (2014), where the period of significant impact is much longer owing to the higher altitude of the initial soot distribution that results in longer residence times of the BC aerosol in the atmosphere. When yearly averages of the same quantities are performed over the IndiaPakistan region, the differences in ensemble mean values lie within the total standard deviations of the two ensembles. The results in Figure 14 can also be compared to the outcomes of other previous studies. In their experiment “UT 1 Tg”, Robock et al. (2007a) found that, when only 1 Tg of soot © 2018 American Geophysical Union. All rights reserved. remains in the atmosphere after the initial rainout, temperature and precipitation anomalies are about 20% of those obtained from their standard 5 Tg BC emission case. Therefore, the largest differences they observed, during the first few years after the exchange, were about - 0.3 K and -0.06 mm/day, respectively, comparable to the anomalies in the top and bottom panels of Figure 14. Their standard 5 Tg emission case resulted in a solar radiation flux anomaly at surface of -12 W/m2 after the second year (see their Figure 3), between 5 and 6 time as large as the corresponding anomalies from our ensembles shown in the middle panel. In their experiment “Exp1”, Stenke et al. (2013) reported global mean surface temperature anomalies not exceeding about 0.3 K in magnitude and precipitation anomalies hovering around -0.07 mm/day during the first few years, again consistent with the results of Figure 14. In a recent study, Pausata et al. (2016) considered the effects of an admixture of BC and organic carbon aerosols, both of which would be emitted in the atmosphere in the aftermath of a nuclear exchange. In particular, they concentrated on the effects of coagulation of these aerosol species and examined their climatic impacts. The initial BC distribution was as in Mills et al. (2014), although the soot burden was released in the atmosphere over time periods of various lengths. Most relevant to our and other previous work are their one-day emission scenarios. They found that, during the first year, the largest values of the atmospheric surface temperature anomalies ranged between about -0.5 and -1.3 K, those of the sea surface temperature anomalies ranged between -0.2 and -0.55 K, and those of the precipitation anomalies varied between -0.15 and -0.2 mm/day. All these ranges are compatible with our results shown in Figure 14 as red lines and with those of Mills et al. (2014, see their Figures 3 and 6). As already mentioned in Section 2.3, the net solar flux anomalies at surface are also consistent. This overall agreement suggests that the **inclusion of organic carbon aerosols, and** ensuing **coagulation** with BC, **should not dramatically alter the climatic effects** resulting from our forced ensemble simulations. Moreover, aerosol growth would likely **shorten the residence time of the BC particulate in the atmosphere** (Pausata et al., 2016), possibly **reducing the duration of these effects.**

#### Deployment of every nuke in existence would destroy at most 1/38th of global land mass – In a realistic deployment, that number is closer to 1/192nd

Hall 19 (Allen Hall – Expert in Aerospace Management, Manufacturing, Engineering and IT, worked closely with the military, research labs, FFRDC’s, AFRL, NAVSEA / NAVAIR, all the major ALC’s and all the aerospace OEM’s. <MKIM> “Who would win in a war between Russia and the US?”. 4/25/19. DOA: 7/17/19. https://www.quora.com/Who-would-win-in-a-war-between-Russia-and-the-US/answer/Allen-E-Hall-2)

If you take every weapon in existence today, approximately 6500 megatons between 15,000 warheads with an average yield of 433 KT, [13] and put a single bomb in its own 100 square mile grid… one bomb per grid (10 miles x 10 miles), y**ou will contain >95% of the destructive force** of each bomb on average **within the grid it is in.** [14] This means the total landmass to receive a destructive force from all the world's nuclear bombs is an area of 1.5 million square miles. Not quite half of the United States and 1/38 of the world's total land mass…. that's it! In truth it would be far less. **A** higher concentration **of detonations would** take place over military targets **and would be likely 10–30 times greater in concentration** over those areas. [15] If they were used in war **it is unlikely more than 40% would get used even in a total war situation**. So the actual area of intense destruction in a nuclear war is somewhere between 150,000 and 300,000 square miles or **1/384 to** 1/192 of the world’s land mass. These numbers are easily verifiable, and they are right. So many have bought into the endless rhetoric of the world shattering destructiveness and the inevitable end of civilization scenarios that they can no longer be objective or analytical as they have put their beliefs in front of rational thinking. I find this true even with most scientists. I challenge anyone to just do the math …it is easy. **You win wars by taking out the opposing teams ability to make war, not their population centers.** The arsenals of today are just enough to cover military objectives. There would be no wholesale war against civilians. **That is just more fear mongering and Hollywood storytelling.**